Pub Date : 2023-08-14DOI: 10.14412/2074-2711-2023-4-4-11
D. V. Zhiznevskiy, M. V. Zamergrad, S. Grachev
Among the various causes of acute vestibular vertigo, vascular factors are of particular importance. Numerous studies show that the diagnosis of vascular vertigo remains inadequate, often leading to overdiagnosis of stroke and transient ischemic attacks in patients with peripheral vestibular disorders and vestibular migraine, on the one hand, and underestimation of the importance of cerebrovascular pathology, especially in patients with the first attack of persistent vestibular vertigo, on the other.The International Barany Society has developed and published diagnostic criteria for vascular vertigo. These criteria are intended to facilitate the identification of vascular causes of acute vestibular syndrome. Particular emphasis is placed on clinical signs because imaging techniques often do not allow detection of foci small in volume and area, especially in cases when stroke is manifested by an isolated vestibular syndrome. Key clinical signs to analyze when a vascular etiology of acute vestibular syndrome is suspected include nystagmus, corrective saccades on the Halmagyi test, smooth visual pursuit, visual saccades, severity of trunk ataxia, and hearing loss.
{"title":"Modern concept of vascular vertigo","authors":"D. V. Zhiznevskiy, M. V. Zamergrad, S. Grachev","doi":"10.14412/2074-2711-2023-4-4-11","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-4-4-11","url":null,"abstract":"Among the various causes of acute vestibular vertigo, vascular factors are of particular importance. Numerous studies show that the diagnosis of vascular vertigo remains inadequate, often leading to overdiagnosis of stroke and transient ischemic attacks in patients with peripheral vestibular disorders and vestibular migraine, on the one hand, and underestimation of the importance of cerebrovascular pathology, especially in patients with the first attack of persistent vestibular vertigo, on the other.The International Barany Society has developed and published diagnostic criteria for vascular vertigo. These criteria are intended to facilitate the identification of vascular causes of acute vestibular syndrome. Particular emphasis is placed on clinical signs because imaging techniques often do not allow detection of foci small in volume and area, especially in cases when stroke is manifested by an isolated vestibular syndrome. Key clinical signs to analyze when a vascular etiology of acute vestibular syndrome is suspected include nystagmus, corrective saccades on the Halmagyi test, smooth visual pursuit, visual saccades, severity of trunk ataxia, and hearing loss.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87374598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-14DOI: 10.14412/2074-2711-2023-4-12-16
D. F. Multamasatika, K. A. Akbar, R. I. Hartanti, K. Kallawicha
Work stress is a discrepancy between the workload and the individual's ability to do their job. Work stress factors that cause work stress are individual, work, and outside the work/environment. There is no data and research about work stress from work factors, mainly focusing on lecturers or universities.Objective. This study aimed to analyze the relationship between work factors in the form of type of faculty, workload, type of professor, and interpersonal relationships with the work stress of lecturers.Material and methods. This research was conducted using a cross-sectional study. The research sample consisted of 100 lecturers with active status selected by quota sampling. Data were collected using a questionnaire filled out online and analyzed using the Chi-square test and the Contingency Coefficient Test.Results. The result showed that most participants had moderate stress (score: 59–92) and moderate workload (score: 50–80). Most of the participants were Associate professors (52%) and had good interpersonal relationships in the workplace (59%). There is a relationship between interpersonal relationships and work stress of lecturers. However, there was no relationship between type of faculty, workload, and type of professor with lecturers' work stress.Conclusion. In conclusion, interpersonal relationships are significantly related to job stress on lecturers. A good interpersonal relationship will reduce the possibility of work stress on the participant.
{"title":"Work factors affect work stress among lecturers: study in Indonesia","authors":"D. F. Multamasatika, K. A. Akbar, R. I. Hartanti, K. Kallawicha","doi":"10.14412/2074-2711-2023-4-12-16","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-4-12-16","url":null,"abstract":"Work stress is a discrepancy between the workload and the individual's ability to do their job. Work stress factors that cause work stress are individual, work, and outside the work/environment. There is no data and research about work stress from work factors, mainly focusing on lecturers or universities.Objective. This study aimed to analyze the relationship between work factors in the form of type of faculty, workload, type of professor, and interpersonal relationships with the work stress of lecturers.Material and methods. This research was conducted using a cross-sectional study. The research sample consisted of 100 lecturers with active status selected by quota sampling. Data were collected using a questionnaire filled out online and analyzed using the Chi-square test and the Contingency Coefficient Test.Results. The result showed that most participants had moderate stress (score: 59–92) and moderate workload (score: 50–80). Most of the participants were Associate professors (52%) and had good interpersonal relationships in the workplace (59%). There is a relationship between interpersonal relationships and work stress of lecturers. However, there was no relationship between type of faculty, workload, and type of professor with lecturers' work stress.Conclusion. In conclusion, interpersonal relationships are significantly related to job stress on lecturers. A good interpersonal relationship will reduce the possibility of work stress on the participant.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74043907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-14DOI: 10.14412/2074-2711-2023-4-17-23
V. Gafarov, E. Gromova, D. Panov, I. Gagulin, A. Gafarova
Objective: to determine the main psychosocial factors associated with sleep disorders in an open population aged 25–64 years in Novosibirsk.Material and methods. Screening studies were conducted on representative samples of the population aged 25–64 years: in 2013–2016. (V screening: 427 men, mean age 34±0.4 years, response rate 71%; 548 women, mean age 35±0.4 years, response rate 72%); in 2015–2018 (VI screening: 275 men, mean age – 49±0.4 years, response rate – 72%; 390 women, mean age – 45±0.4 years, response rate – 75%) (budget topic No. АААА-А17-117112850280-2) using the protocol of the WHO international program “MONICA-psychosocial”. The Jenkins questionnaire was used in the population survey to investigate sleep disorders. To examine personal anxiety, a form of the Spielberger Self-Assessment Scale was used; to determine depression, life exhaustion, and hostility, the MOPSY-test was used; and to examine social support, the Berkman-Syme test was used.Results. In the open population aged 25 to 64 years, sleep disorders were found in 47.6% of men and 51.2% of women. Among those with sleep disorders, we found high levels of: anxiety (HLA) in 61.8% of men (χ2=56.169; df=4; p<0.001) and 68.1% of women (χ2=36.535; df=4; p<0.001); depression (HLD) – in 18.2% of men (χ2=26.609; df=4; p<0.001) and 20% of women (χ2=41.041; df=4; p<0.001); vital exhaustion (VE) – in 63.6% of men (χ2=93.378; df=4; p<0.001) and 59.3% of women (χ2=124.115; df=4; p<0.001); hostility (HLH) – in 52.7% of men (χ2=17.598; df=4; p<0.001) and 39.3% of women (χ2=13.139; df=4; p<0.01).We found no statistically significant differences between groups of men and women, who differed in sleep self-essessment and indicators of the index of close contacts and the index of social ties.Sleep disturbances increased the likelihood of developing of VE (OR 2.301; 95% СI 1.774–2.984; p<0.0001), HLA (OR 1.882; 95% CI 1.199–2.955; p<0.006), depression (OR 1.423; 95% CI 1.099–1.842; p<0.007). In men, sleep disturbances contributed to: HLA (OR 2.477; 95% CI 1.303–4.709; p<0.006), VE (OR 2.282; 95% CI 1.529–3.404; p<0.0001). In the group of women with sleep problems, the probability of VE increased (OR 2.37; 95% CI 1.669–3.366; p<0.0001).Conclusion. The study found that in an open population aged 25–64 years with sleep disorders, there was a high level of psychosocial factors and that the presence of sleep disorders increased the likelihood of developing psychosocial factors.
目的:确定与新西伯利亚25-64岁开放人群睡眠障碍相关的主要社会心理因素。材料和方法。2013-2016年对25-64岁人群的代表性样本进行筛查研究。(V)筛查:男性427人，平均年龄34±0.4岁，有效率71%;女性548例，平均年龄35±0.4岁，有效率72%);2015-2018年(VI筛查:男性275人，平均年龄- 49±0.4岁，有效率- 72%;390名女性，平均年龄- 45±0.4岁，回复率- 75%)。АААА-А17-117112850280-2)，使用世卫组织国际规划“monica -社会心理”的协议。詹金斯问卷在人口调查中用于调查睡眠障碍。为了检查个人焦虑，使用了斯皮尔伯格自我评估量表;采用MOPSY-test来确定抑郁、生活疲惫和敌意;为了检验社会支持，我们使用了伯克曼-赛姆测试。在25岁至64岁的开放人群中，47.6%的男性和51.2%的女性存在睡眠障碍。在睡眠障碍患者中，我们发现61.8%的男性HLA水平较高(χ2=56.169;df = 4;P <0.001)，女性为68.1% (χ2=36.535;df = 4;p < 0.001);抑郁症(HLD)——18.2%的男性(χ2=26.609;df = 4;P <0.001)和20%的女性(χ2=41.041;df = 4;p < 0.001);63.6%的男性有生命衰竭(VE) (χ2=93.378;df = 4;P <0.001)，女性为59.3% (χ2=124.115;df = 4;p < 0.001);敌意(HLH) - 52.7%的男性(χ2=17.598;df = 4;P <0.001)，女性为39.3% (χ2=13.139;df = 4;p < 0.01)。我们没有发现男性和女性在睡眠自我评估、密切接触指数和社会关系指数方面的差异有统计学意义。睡眠障碍增加VE发生的可能性(OR 2.301;95% Сi 1.774-2.984;p<0.0001)， HLA (OR 1.882;95% ci 1.199-2.955;p<0.006)，抑郁(OR 1.423;95% ci 1.099-1.842;p < 0.007)。在男性中，睡眠障碍导致:HLA (OR 2.477;95% ci 1.303-4.709;p<0.006)， VE (OR 2.282;95% ci 1.529-3.404;p < 0.0001)。在有睡眠问题的女性组中，VE的概率增加(OR 2.37;95% ci 1.669-3.366;.Conclusion p < 0.0001)。研究发现，在25-64岁有睡眠障碍的开放人群中，存在高水平的社会心理因素，睡眠障碍的存在增加了发展社会心理因素的可能性。
{"title":"Psychosocial factors and sleep disorders in the population aged 25–64 years in Russia/Siberia (International WHO MONICA-Psychosocial Programme)","authors":"V. Gafarov, E. Gromova, D. Panov, I. Gagulin, A. Gafarova","doi":"10.14412/2074-2711-2023-4-17-23","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-4-17-23","url":null,"abstract":"Objective: to determine the main psychosocial factors associated with sleep disorders in an open population aged 25–64 years in Novosibirsk.Material and methods. Screening studies were conducted on representative samples of the population aged 25–64 years: in 2013–2016. (V screening: 427 men, mean age 34±0.4 years, response rate 71%; 548 women, mean age 35±0.4 years, response rate 72%); in 2015–2018 (VI screening: 275 men, mean age – 49±0.4 years, response rate – 72%; 390 women, mean age – 45±0.4 years, response rate – 75%) (budget topic No. АААА-А17-117112850280-2) using the protocol of the WHO international program “MONICA-psychosocial”. The Jenkins questionnaire was used in the population survey to investigate sleep disorders. To examine personal anxiety, a form of the Spielberger Self-Assessment Scale was used; to determine depression, life exhaustion, and hostility, the MOPSY-test was used; and to examine social support, the Berkman-Syme test was used.Results. In the open population aged 25 to 64 years, sleep disorders were found in 47.6% of men and 51.2% of women. Among those with sleep disorders, we found high levels of: anxiety (HLA) in 61.8% of men (χ2=56.169; df=4; p<0.001) and 68.1% of women (χ2=36.535; df=4; p<0.001); depression (HLD) – in 18.2% of men (χ2=26.609; df=4; p<0.001) and 20% of women (χ2=41.041; df=4; p<0.001); vital exhaustion (VE) – in 63.6% of men (χ2=93.378; df=4; p<0.001) and 59.3% of women (χ2=124.115; df=4; p<0.001); hostility (HLH) – in 52.7% of men (χ2=17.598; df=4; p<0.001) and 39.3% of women (χ2=13.139; df=4; p<0.01).We found no statistically significant differences between groups of men and women, who differed in sleep self-essessment and indicators of the index of close contacts and the index of social ties.Sleep disturbances increased the likelihood of developing of VE (OR 2.301; 95% СI 1.774–2.984; p<0.0001), HLA (OR 1.882; 95% CI 1.199–2.955; p<0.006), depression (OR 1.423; 95% CI 1.099–1.842; p<0.007). In men, sleep disturbances contributed to: HLA (OR 2.477; 95% CI 1.303–4.709; p<0.006), VE (OR 2.282; 95% CI 1.529–3.404; p<0.0001). In the group of women with sleep problems, the probability of VE increased (OR 2.37; 95% CI 1.669–3.366; p<0.0001).Conclusion. The study found that in an open population aged 25–64 years with sleep disorders, there was a high level of psychosocial factors and that the presence of sleep disorders increased the likelihood of developing psychosocial factors.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90532904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-128-138
O. Gromova, I. Torshin
We present the results of a systemic biological analysis of human proteome proteins, biological functions of which are somehow related to the metabolism of B group vitamins and the molecular implementation of nociceptive processes. Among 983 proteins involved in the homeostasis of B vitamins, 21 proteins were involved in the molecular mechanisms of nociception, 91 proteins were involved in the regulation of inflammation processes, and 17 proteins were involved in the neuroprotective and neurotrophic effects of B vitamins. All these groups of proteins are important for the treatment of neuropathic pain associated with the degeneration of nervous tissue.
{"title":"Molecular mechanisms of synergistic analgesic and neuroprotective action of B group vitamins according to the results of proteomic analysis","authors":"O. Gromova, I. Torshin","doi":"10.14412/2074-2711-2023-3-128-138","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-128-138","url":null,"abstract":"We present the results of a systemic biological analysis of human proteome proteins, biological functions of which are somehow related to the metabolism of B group vitamins and the molecular implementation of nociceptive processes. Among 983 proteins involved in the homeostasis of B vitamins, 21 proteins were involved in the molecular mechanisms of nociception, 91 proteins were involved in the regulation of inflammation processes, and 17 proteins were involved in the neuroprotective and neurotrophic effects of B vitamins. All these groups of proteins are important for the treatment of neuropathic pain associated with the degeneration of nervous tissue.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76041433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-95-103
E. Katunina, Z. Zalyalova, D. Pokhabov, M. Ivanova, A. Semenova
The review presents current data on the peculiarities of the neurodegenerative process in the early stages of Parkinson’s disease (PD) and considers the hypothesis of the presence of body-first and brain-first subtypes of the disease onset. The earliest manifestations of the disease include symptoms such as parasomnia, constipation, hyposmia, anxiety-depressive disorder, daytime sleepiness, color perception changes, cognitive dysfunction, and mild motor manifestations. The diagnosis of PD can be made when characteristic motor manifestations occur: hypokinesia, rest tremor, muscle rigidity. Substantia nigra ultrasound, magnetic resonance imaging in SWI mode, and functional neuroimaging methods are used as confirmatory methods. The approach to the treatment of early stages of PD is age dependent. Patients over 70 years of age are recommended to start therapy with levodopa; younger patients – with dopamine receptor agonists (ADR), amantadines, MAO-B inhibitors. The mechanisms of ADR action, the possibility of their influence on the motor and non-motor symptoms of PD are analyzed. A special place is given to piribedil, which, due to the dual mechanism of action, has a positive effect on cognitive functions, depression, apathy, as well as a minimal effect on daytime sleepiness.
{"title":"Parkinson’s disease. Focus on early stages","authors":"E. Katunina, Z. Zalyalova, D. Pokhabov, M. Ivanova, A. Semenova","doi":"10.14412/2074-2711-2023-3-95-103","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-95-103","url":null,"abstract":"The review presents current data on the peculiarities of the neurodegenerative process in the early stages of Parkinson’s disease (PD) and considers the hypothesis of the presence of body-first and brain-first subtypes of the disease onset. The earliest manifestations of the disease include symptoms such as parasomnia, constipation, hyposmia, anxiety-depressive disorder, daytime sleepiness, color perception changes, cognitive dysfunction, and mild motor manifestations. The diagnosis of PD can be made when characteristic motor manifestations occur: hypokinesia, rest tremor, muscle rigidity. Substantia nigra ultrasound, magnetic resonance imaging in SWI mode, and functional neuroimaging methods are used as confirmatory methods. The approach to the treatment of early stages of PD is age dependent. Patients over 70 years of age are recommended to start therapy with levodopa; younger patients – with dopamine receptor agonists (ADR), amantadines, MAO-B inhibitors. The mechanisms of ADR action, the possibility of their influence on the motor and non-motor symptoms of PD are analyzed. A special place is given to piribedil, which, due to the dual mechanism of action, has a positive effect on cognitive functions, depression, apathy, as well as a minimal effect on daytime sleepiness.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78923558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-82-84
R. Bidaki, Z. Salimi, R. Naderi Deh Ghotbadini, S. Amiri Gavar, F. Dehghani
Gender Dysphoria (GD) is defined as a marked incongruence between one’s experienced/expressed gender and assigned gender that the individual feels a strong desire for having the sex characteristics of the other gender. Twin studies could be helpful in making decisive conclusion on the relative role of genetics and environment on GD. Therefore, we hereby present a case of monozygotic twins with concordant female-to-male GD. Seventeen-year-old twins are introduced in this case report. The second pair attended to our clinic for psychiatric evaluation. She was suffering from GD by overwhelmed desire for having masculine features, wearing their cloths, and at the same time revolting being a girl. Although she preferred spending time with male friends, she was sexually attracted to females. Although the first pair had similar characteristics of GD, she presented apposite temperament. While temperament has been considered to be genetically inherited, the incidence of GD in our cases with different temperaments raises the question about genetic role in inheriting temperament and GD. Further twin studies will help understanding the extent of genetic influence on these features.
{"title":"Monozygotic twins with concordant female-to-male gender dysphoria with different temperament characteristics: a case report","authors":"R. Bidaki, Z. Salimi, R. Naderi Deh Ghotbadini, S. Amiri Gavar, F. Dehghani","doi":"10.14412/2074-2711-2023-3-82-84","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-82-84","url":null,"abstract":"Gender Dysphoria (GD) is defined as a marked incongruence between one’s experienced/expressed gender and assigned gender that the individual feels a strong desire for having the sex characteristics of the other gender. Twin studies could be helpful in making decisive conclusion on the relative role of genetics and environment on GD. Therefore, we hereby present a case of monozygotic twins with concordant female-to-male GD. Seventeen-year-old twins are introduced in this case report. The second pair attended to our clinic for psychiatric evaluation. She was suffering from GD by overwhelmed desire for having masculine features, wearing their cloths, and at the same time revolting being a girl. Although she preferred spending time with male friends, she was sexually attracted to females. Although the first pair had similar characteristics of GD, she presented apposite temperament. While temperament has been considered to be genetically inherited, the incidence of GD in our cases with different temperaments raises the question about genetic role in inheriting temperament and GD. Further twin studies will help understanding the extent of genetic influence on these features.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81776142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-104-113
M. Perez, N. Zavadenko, L. Skipetrova, I. I. Smirnov, Y. Nesterovskiy
The review presents the results of clinical studies of the efficacy and safety of Tenoten and Tenoten children’s in the treatment of anxiety, neurotic, stress-related and somatoform disorders and adjustment disorders. Technologically processed antibodies to the S100 protein in Tenoten and Tenoten children’s drugs change the conformation of the S100 protein, which is considered as a pathological link in the development of anxiety states, as well as neurodegenerative diseases. Tenoten is a well-studied daytime anxiolytic that combines a favorable safety profile with high anxiolytic activity. The efficacy of Tenoten in the treatment of anxiety disorders is comparable to that of benzodiazepine drugs. Tenoten has no inhibitory and muscle relaxant effects, does not cause drug tolerance, addiction, "withdrawal" syndrome, as well as drug interactions. Tenoten for children has been shown to be effective in the treatment of anxiety in children, including those with somatic manifestations, attention deficit hyperactivity disorder, and learning disabilities.
{"title":"Efficacy and safety of a daytime anxiolytic containing technologically processed antibodies to the S100 protein. Overview of clinical studies","authors":"M. Perez, N. Zavadenko, L. Skipetrova, I. I. Smirnov, Y. Nesterovskiy","doi":"10.14412/2074-2711-2023-3-104-113","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-104-113","url":null,"abstract":"The review presents the results of clinical studies of the efficacy and safety of Tenoten and Tenoten children’s in the treatment of anxiety, neurotic, stress-related and somatoform disorders and adjustment disorders. Technologically processed antibodies to the S100 protein in Tenoten and Tenoten children’s drugs change the conformation of the S100 protein, which is considered as a pathological link in the development of anxiety states, as well as neurodegenerative diseases. Tenoten is a well-studied daytime anxiolytic that combines a favorable safety profile with high anxiolytic activity. The efficacy of Tenoten in the treatment of anxiety disorders is comparable to that of benzodiazepine drugs. Tenoten has no inhibitory and muscle relaxant effects, does not cause drug tolerance, addiction, \"withdrawal\" syndrome, as well as drug interactions. Tenoten for children has been shown to be effective in the treatment of anxiety in children, including those with somatic manifestations, attention deficit hyperactivity disorder, and learning disabilities.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81048907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-68-75
J. Azimova, Y. Sivolap, K. Ishchenko
The prolonged release tablets form of alimemazine is seen as a promising agent for the long-term treatment of generalized anxiety disorder (GAD).Objective: to investigate the efficacy and safety of therapy with alimemazine (Teraligen® retard, prolonged release film-coated tablets) in patients with GAD.Material and methods. The study design was a multicentre, open-label, non-comparative clinical trial (CT) with two doses of alimemazine 20 and 40 mg (Teraligen® retard, prolonged-release film-coated tablets). 129 patients diagnosed with GAD (criteria according to the ICD-10 classification), 86 women and 43 men were included, mean age 38.0±11.1 years. The level of anxiety, assessed by the Hamilton HARS scale, at Week 0 (Visit 1) was 24.8±7.3 points.Results. By Week 6, the level of anxiety statistically significantly decreased to a mean score of 10.8±6.6, while the dynamics of the mean score relative to baseline was -14.0±6.27 (p<0.0001). The proportion of patients with a decrease in the total score on the HARS scale by 50% or more compared with the initial value was: after 1 week of therapy – 10.3% (n=13); after 3 weeks of therapy – 60.5% (n=75; compared to baseline, p<0.0001); after 6 weeks of therapy – 69.4% (n=86; compared to baseline, p<0.0001). The therapy was well tolerated, among the adverse events (AEs) patients noted: morning sleepiness (7.8%; n=10); dry mouth (7.8%; n=10); general weakness (4.7%; n=6). Other AEs (dizziness, headache, impaired concentration, muscle weakness, memory impairment, tinnitus, tachycardia) were much less common. From the side of the liver, no AEs were detected, including changes in the activity of liver enzymes.Conclusion. Prolonged release alimemazine tablets 20 mg and 40 mg for six weeks resulted in a statistically significant reduction in anxiety levels, with at least two-thirds of patients experiencing more than half their anxiety. The effect increases with each week as you continue to take the drug. The prolonged release form of alimemazine is well tolerated, the treatment of GAD with the drug is effective and safe and may represent a rational alternative to antidepressant therapy.
{"title":"Clinical effectiveness and safety of prolonged release form of alimemazine in patients with generalized anxiety disorder","authors":"J. Azimova, Y. Sivolap, K. Ishchenko","doi":"10.14412/2074-2711-2023-3-68-75","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-68-75","url":null,"abstract":"The prolonged release tablets form of alimemazine is seen as a promising agent for the long-term treatment of generalized anxiety disorder (GAD).Objective: to investigate the efficacy and safety of therapy with alimemazine (Teraligen® retard, prolonged release film-coated tablets) in patients with GAD.Material and methods. The study design was a multicentre, open-label, non-comparative clinical trial (CT) with two doses of alimemazine 20 and 40 mg (Teraligen® retard, prolonged-release film-coated tablets). 129 patients diagnosed with GAD (criteria according to the ICD-10 classification), 86 women and 43 men were included, mean age 38.0±11.1 years. The level of anxiety, assessed by the Hamilton HARS scale, at Week 0 (Visit 1) was 24.8±7.3 points.Results. By Week 6, the level of anxiety statistically significantly decreased to a mean score of 10.8±6.6, while the dynamics of the mean score relative to baseline was -14.0±6.27 (p<0.0001). The proportion of patients with a decrease in the total score on the HARS scale by 50% or more compared with the initial value was: after 1 week of therapy – 10.3% (n=13); after 3 weeks of therapy – 60.5% (n=75; compared to baseline, p<0.0001); after 6 weeks of therapy – 69.4% (n=86; compared to baseline, p<0.0001). The therapy was well tolerated, among the adverse events (AEs) patients noted: morning sleepiness (7.8%; n=10); dry mouth (7.8%; n=10); general weakness (4.7%; n=6). Other AEs (dizziness, headache, impaired concentration, muscle weakness, memory impairment, tinnitus, tachycardia) were much less common. From the side of the liver, no AEs were detected, including changes in the activity of liver enzymes.Conclusion. Prolonged release alimemazine tablets 20 mg and 40 mg for six weeks resulted in a statistically significant reduction in anxiety levels, with at least two-thirds of patients experiencing more than half their anxiety. The effect increases with each week as you continue to take the drug. The prolonged release form of alimemazine is well tolerated, the treatment of GAD with the drug is effective and safe and may represent a rational alternative to antidepressant therapy.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77144668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-48-53
E. B. Kuznetsova, O. N. Voskresenskaya, N. Zakharova, N. S. Kuznetsov
Objective: to study the level of inflammatory biomarkers and growth factors in the peripheral blood of patients with chronic cerebrovascular disease (CCVD) and anamnesis of coronavirus infection COVID-19.Material and methods. The study included patients with CCVD (n=41), 26 of them had a documented anamnesis of coronavirus infection within 4 months before inclusion in the study, 15 people did not have COVID-19. The control group consisted of 20 apparently healthy individuals of the same age. Neuroimaging was performed using a Philips Achieva 1.5 T device. Pro-inflammatory cytokines were determined in blood serum – tumor necrosis factor α (TNF α ), interleukin 6 (IL6), IL18, interferon γ (IFN γ ); chemokines – monocytic chemoattractant protein 1 (MCP-1), IL8; growth factors – vascular endothelial growth factor type A (VEGF-A), transforming growth factor β 1 (TGF β 1).Results. In patients with CCVD, compared with the control group, an increase in the level of proinflammatory cytokines (TNF α , IL6, IL18), chemokines (MCP1 and IL8), a decrease in the concentration of IFN γ , and divergent changes in the content of growth factors (VEGF-A and TGF β 1) were noted. Patients who recovered from COVID-19 showed an increase in the level of IL6 and a decrease in the level of IFN γ compared with those who had not been ill, which indicates a persistently high activity of immunoinflammatory processes and an insufficient humoral immune response.Conclusion. Postponed coronavirus infection COVID-19 aggravates the existing endothelial dysfunction and intravascular inflammation in patients with CCVD, which may probably require changes in their treatment and prevention strategies in the future.
{"title":"Inflammatory biomarkers and growth factors in patients with chronic cerebrovascular disease after coronavirus infection","authors":"E. B. Kuznetsova, O. N. Voskresenskaya, N. Zakharova, N. S. Kuznetsov","doi":"10.14412/2074-2711-2023-3-48-53","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-48-53","url":null,"abstract":"Objective: to study the level of inflammatory biomarkers and growth factors in the peripheral blood of patients with chronic cerebrovascular disease (CCVD) and anamnesis of coronavirus infection COVID-19.Material and methods. The study included patients with CCVD (n=41), 26 of them had a documented anamnesis of coronavirus infection within 4 months before inclusion in the study, 15 people did not have COVID-19. The control group consisted of 20 apparently healthy individuals of the same age. Neuroimaging was performed using a Philips Achieva 1.5 T device. Pro-inflammatory cytokines were determined in blood serum – tumor necrosis factor α (TNF α ), interleukin 6 (IL6), IL18, interferon γ (IFN γ ); chemokines – monocytic chemoattractant protein 1 (MCP-1), IL8; growth factors – vascular endothelial growth factor type A (VEGF-A), transforming growth factor β 1 (TGF β 1).Results. In patients with CCVD, compared with the control group, an increase in the level of proinflammatory cytokines (TNF α , IL6, IL18), chemokines (MCP1 and IL8), a decrease in the concentration of IFN γ , and divergent changes in the content of growth factors (VEGF-A and TGF β 1) were noted. Patients who recovered from COVID-19 showed an increase in the level of IL6 and a decrease in the level of IFN γ compared with those who had not been ill, which indicates a persistently high activity of immunoinflammatory processes and an insufficient humoral immune response.Conclusion. Postponed coronavirus infection COVID-19 aggravates the existing endothelial dysfunction and intravascular inflammation in patients with CCVD, which may probably require changes in their treatment and prevention strategies in the future.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77471754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-04DOI: 10.14412/2074-2711-2023-3-41-47
N. Zarubina, N. Spirin
Multiple sclerosis (MS) is a neurodegenerative disease that leads to multiple focal and diffuse lesions of the central nervous system, resulting in disability of patients. Currently the impact of depression on the quality of life (QoL) of MS patients has been little studied.Objective: to study the effect of depressive disorders on the QoL of patients with MS, to search for factors influencing the development of depression in patients with MS.Material and methods. The study involved 203 MS patients aged 15 to 60 years (mean age 39.7±10.91 years). Disability according to the EDSS scale was 2.51±1.45 points, the average duration of the disease was 8.07±7.22 years. The comparison group consisted of 52 healthy people aged 24 to 43 years (mean age 31.86±6.98 years).Results. Patients with MS in more than half of cases (55.7%) suffer from depressive disorders. In MS patients there was an association of depression with older age, a longer duration of the disease, as well as a higher level of disability and exacerbations (p<0.001). MS patients with depression significantly more often (p<0.01) complained of increased fatigue and had higher scores on the scales of asthenia, situational and personal anxiety, and were also exposed to stressful influences and tolerated them poorly; they were more likely than those of the control group to had depressive episodes earlier. MS patients with depression had lower scores (p<0.001) for all QoL criteria, which further accelerated their disability and social isolation.Conclusion. Depression in MS patients has a negative impact on all QoL indicators.
{"title":"Impact of depression on the quality of life of patients with multiple sclerosis","authors":"N. Zarubina, N. Spirin","doi":"10.14412/2074-2711-2023-3-41-47","DOIUrl":"https://doi.org/10.14412/2074-2711-2023-3-41-47","url":null,"abstract":"Multiple sclerosis (MS) is a neurodegenerative disease that leads to multiple focal and diffuse lesions of the central nervous system, resulting in disability of patients. Currently the impact of depression on the quality of life (QoL) of MS patients has been little studied.Objective: to study the effect of depressive disorders on the QoL of patients with MS, to search for factors influencing the development of depression in patients with MS.Material and methods. The study involved 203 MS patients aged 15 to 60 years (mean age 39.7±10.91 years). Disability according to the EDSS scale was 2.51±1.45 points, the average duration of the disease was 8.07±7.22 years. The comparison group consisted of 52 healthy people aged 24 to 43 years (mean age 31.86±6.98 years).Results. Patients with MS in more than half of cases (55.7%) suffer from depressive disorders. In MS patients there was an association of depression with older age, a longer duration of the disease, as well as a higher level of disability and exacerbations (p<0.001). MS patients with depression significantly more often (p<0.01) complained of increased fatigue and had higher scores on the scales of asthenia, situational and personal anxiety, and were also exposed to stressful influences and tolerated them poorly; they were more likely than those of the control group to had depressive episodes earlier. MS patients with depression had lower scores (p<0.001) for all QoL criteria, which further accelerated their disability and social isolation.Conclusion. Depression in MS patients has a negative impact on all QoL indicators.","PeriodicalId":19252,"journal":{"name":"Neurology, neuropsychiatry, Psychosomatics","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88333847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：